Fig. 3.

Patients were divided in two groups: in the first one, indicated with empty circles, the number of Vδ2 T lymphocytes did not decrease after zoledronic acid treatment; in the second one, indicated with filled circles, the number of T Vδ2 lymphocytes decreased significantly after zoledronic acid treatment. The figure shows the changes in the total CD3+/Vδ2 T lymphocytes (a) and of the different subsets: Naïve (CD45RA+/CD27+; b), Central Memory (CM; CD45RA−/CD27+; c), Effector Memory (CD45RA−/CD27-; d), Terminal Effector (CD45RA+/CD27−; e) in patients of each group. Values are expressed as indexes with respect to the individual baseline values before zoledronic acid treatment. Columns indicate median and interquartil-range (IQR) of each group. Results of Wilcoxon Matched-Pairs Signed-Ranks Test compared with the basal value: * P < 0.05, ** P < 0.01